Neurotrope (NTRP) EBITDA margin US GAAP (year values) |
|||||||||
| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -440.7% | -1 108% | -1 536% | -398.4% | -587.0% | |||
| Changes by years, y/y, % | +189pp | -667pp | +1 108pp | +1 137pp | -8.7% | ||||
Neurotrope. EBITDA margin, %
Neurotrope. EBITDA margin, changes, pp
Neurotrope (NTRP) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q4 | FY2026Q1 | FY2026Q2 | FY2026Q3 | FY2026Q4 | LTM ? | |||
| EBITDA margin, % | ? | -3 637% | -2 855% | -394.1% | -234.3% | -282.4% | -587.0% | |
| Changes by years, y/y, % | +1 340pp | +1 943pp | +3 355pp | |||||
| Changes by quarters, q/q, % | -1 460pp | +782pp | +2 460pp | +160pp | -48pp | |||